ALFA Finder| Revenue growth | 23.6% INR growth; 18.2% USD growth for FY26. |
|---|---|
| Margins | Temporary 150bps impact from investments; recovery expected by H2FY27. |
| Order book | Closed 8 major ACV deals in Q4 including $3M+ clinical win. |
| Demand visibility | Strong pipeline entering FY27; high adoption of AI-led mandates. |
| Management confidence | High; transitioning from 'cautiously optimistic' to 'excited and confident'. |
Growth
FY26 revenue up 23.6% to ₹35,105M; Q4 adjusted EBITDA grew 23.2% YoY to ₹1,889M.
Outlook
Expects EBITDA margins to revert to historical highs in H2FY27; no formal revenue guidance provided.
Risks
Legal provision of ₹203M for US TCPA lawsuit; currency volatility impacting unexpired forward contracts.
Earnings Call filed with NSE, NSE: INDGN. Summary written with AI assistance from the document.
Indegene Ltd: key numbers
- Share price
- ₹616.00
- Market cap
- ₹14,841 Cr
- Revenue (annual)
- ₹3,510 Cr
- Net profit (annual)
- ₹401.1 Cr
- P/E (TTM)
- 36.1×Sector 54.5×
- Promoter holding
- 0.00%+0.00% QoQ
- FII holding
- 12.40%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Indegene Ltd
All →Indegene Earnings Call Transcript: Key Takeaways
Strong top-line growth driven by pharma digital transformation, but near-term margins are compressed by annual wage hikes and mutual fund mark-downs.
Indegene Management Change
Indegene's Company Secretary and Compliance Officer Srishti Ramesh Kaushik resigned, effective 02-Dec-2026. The resignation cites future career advancement.
Indegene Employee Stock Options
Indegene Limited allotted 52,194 equity shares under its ESOP schemes, raising paid-up capital to Rs.48.21 Crore. No cash fund raise is involved, so no event value applies.
Indegene Investor Presentation: Key Takeaways
Q2 FY27 revenue INR 11,223M (+39.5% YoY, +5.6% QoQ), EBITDA margin 16.7%, PAT INR 1,123M (+10% YoY). BioPharm integration ahead of plan.
Indegene Results Update
Indegene reported Q2 FY27 revenue of ₹11,223M, up 39.5% YoY, with PAT of ₹1,123M. H1 USD revenue growth reached a four-year high of 27.0%.
Indegene Q2 FY27 Results: Net Profit ₹112.3 Cr, Up 10.0% YoY
Indegene Ltd reported revenue from operations of ₹1,122 Cr (+39.6% YoY) and net profit of ₹112.3 Cr (+10.0% YoY) for Q2 FY27.
- Key figure
- Net profit ₹112.3 Cr · +10.0% YoY